Artelo Biosciences (ARTL) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on therapeutics targeting lipid-signaling pathways, including the endocannabinoid system.

• Pipeline includes ART27.13 (dual CB1/CB2 agonist for cancer-related anorexia), ART26.12 (FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and other indications), and ART12.11 (CBD/TMP cocrystal for multiple potential uses).

• Product candidates are developed through in-licensing and internal discovery, with a strategy to retain commercialization rights but open to partnerships.

• Intellectual property portfolio includes composition of matter patents and global filings for key assets.

Financial performance and metrics

• As of March 23, 2026, 736,127 shares of common stock were outstanding.

• Company has received research grants and R&D tax credits, but faces ongoing need for additional financing to support operations.

• Recent bridge notes issued in March 2026 for $237,300 and $113,000, both maturing in January 2027.

Use of proceeds and capital allocation

• May receive up to $50 million in gross proceeds from sales of common stock to Square Gate under the ELOC Purchase Agreement.

• Proceeds are expected to be used for working capital and general corporate purposes, with management retaining broad discretion over allocation.